Cargando…
Intravesical Mycobacterium brumae triggers both local and systemic immunotherapeutic responses against bladder cancer in mice
The standard treatment for high-risk non-muscle invasive bladder cancer (BC) is the intravesical administration of live Mycobacterium bovis BCG. Previous studies suggest improving this therapy by implementing non-pathogenic mycobacteria, such as Mycobacterium brumae, and/or different vehicles for my...
Autores principales: | Noguera-Ortega, Estela, Rabanal, Rosa M., Gómez-Mora, Elisabet, Cabrera, Cecilia, Luquin, Marina, Julián, Esther |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180069/ https://www.ncbi.nlm.nih.gov/pubmed/30305693 http://dx.doi.org/10.1038/s41598-018-33253-w |
Ejemplares similares
-
Draft Genome Sequence of Mycobacterium brumae ATCC 51384
por: D'Auria, Giuseppe, et al.
Publicado: (2016) -
Mycolicibacterium brumae is a Safe and Non-Toxic Immunomodulatory Agent for Cancer Treatment
por: Bach-Griera, Marc, et al.
Publicado: (2020) -
Mycobacterial surface characters remodeled by growth conditions drive different tumor-infiltrating cells and systemic IFN-γ/IL-17 release in bladder cancer treatment
por: Guallar-Garrido, Sandra, et al.
Publicado: (2022) -
Mycobacteria emulsified in olive oil-in-water trigger a robust immune response in bladder cancer treatment
por: Noguera-Ortega, Estela, et al.
Publicado: (2016) -
Brumas : poemas
por: Richard, Ramón R.
Publicado: (1934)